New drugs for diabetes and obesity will be released in Korea next month...Interested in the competition with Hugo Bee
Jul 24, 2025
|
In the middle of next month, Korea Lily announced that it will release 2.5 and 5mg/0.5ml of the GIP (glucagon-like peptide-1) receptor dual efficacy drugs 'Freefield Penju' (component name Terzepatide) for domestic type 2 diabetes and obesity patients.
Maunzaro, the only GIP/GLP-1 receptor dual efficacy agent in the world, has been approved in South Korea as an adjuvant for dietary and exercise regulation to improve glycemic control in adult type 2 diabetes patients and as an adjuvant for low-calorie diet and exercise regimen for chronic weight management in adult obesity (initial body mass index, BMI above 30), or overweight (initial BMI above 27 and below 30) patients with one weight-related comorbidities.
The World Health Organization (WHO) classifies Maunzaro as a treatment in a different family than the existing GLP-1 receptor agonist.
A single-molecule injection designed to selectively bind to and activate GIP and GLP-1 receptors with a single weekly dose, helping to promote insulin secretion and improve insulin sensitivity, drop blood sugar through reduced glucagon concentration, reduce food intake through delayed gastric emptying, and lose weight.
Meanwhile, the related industry is focusing on the competition between Novo Nordisk's 'Wigobi' (Semaglutide) and Mountaineer, which dominate the domestic market. With sales of 79.4 billion won in Korea in the first quarter of this year, Hugo Bee's share in the domestic obesity treatment market reached 73.1%, and in the global market, latecomer Mountaineer is rapidly encroaching on the market.
This article was translated by Naver AI translator.
